Vaccines, which can be complicated and expensive to manufacture, haven't always been the moneymakers they are for some drugmakers today. Last year, the global vaccines market topped $25.56 billion according to EvaluatePharma, with the world's 6 top-selling shots each cracking the blockbuster barrier.
It's a small group of drugmakers that are enjoying vaccines' top-line success. The top three vaccine players--Merck, Sanofi and GlaxoSmithKline, in that order--generated nearly two-thirds of that haul, EP says. Add Pfizer and Novartis to round out the top 5, and the group raked in more than 86% of all vaccine sales.
For now, these 5 are at the front of the pack. Take a look at the report to see how they're doing it and what lies ahead as they look to maintain their leads--or bow out, as the case may be.
Pfizer's Prevnar 13 currently dominates the list of the world's best-selling vaccines--and that won't be changing anytime soon, according to a new report from EvaluatePharma. In fact, it's expected to widen its lead, with sales growing more than 61% over the next 5+ years; by 2020, it will be generating nearly $4 billion more than runner up Pentacel from Sanofi, EP predicts.
As far as the rest of the list, however, EP anticipates a bit of shuffling. Merck's Gardasil, last year's No. 2 seller, will slide into third place to make room for Pentacel. And GlaxoSmithKline's Pediarix will inch up into fifth, knocking Merck's varicella jab Varivax out of the top 5.
Take a look at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013.
The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top. The "go big or go home" mentality has sent Novartis packing, with the Swiss company selling GSK most of its vaccines unit earlier this year as it made moves to exit the space. Pfizer, on the other hand, is scouting for ways to bulk up, earlier this month listing AstraZeneca's vaccine assets among the benefits of a potential merger.
For now, though, behind Pfizer's market-leading Prevnar 13, it's jabs from the leading triumvirate that bring in the bulk of vaccine sales. Merck, in particular, took four of the 10 top-selling spots, with Glaxo and Sanofi nabbing two apiece.
POPULAR COMMENT THREADS
Let the uptake begin. Pfizer has snagged the CDC panel recommendation for Prevnar 13 it's been looking for--a nod for use in adults over the age of 65. And that should result in a sales lift that analysts say could touch $2 billion in peak additional sales potential--for now.
Back in 2012, researchers flagged some positive results for patient subgroups in a flunked trial of Merck KGaA's cancer vaccine. But now, the vaccine has hit another snag, failing to hit its primary endpoint--as well as three secondary endpoints--in a Japanese trial, partner Oncothyreon said Monday in an SEC filing.
Pfizer and Novartis are in a dead heat to become the first vaccinemaker to roll out a meningitis B vaccine for the U.S. market. But the New York pharma giant just became the first of the two to snag a decision date from the FDA, which says it will have an answer on Pfizer's candidate within the next 6 months.
As Africa continues to experience the most severe Ebola outbreak in the disease's short history, the World Health Organization has deemed it ethical to offer unregistered interventions as potential treatments or preventive therapies, including investigational vaccines.
Sanofi appealed to the FDA to change the labeling of its high-dose Fluzone vaccine to reflect superior efficacy data in people aged over 65, and now it has fresh trial results to back up its case that Fluzone High-Dose provides better protection in individuals in this age group compared to traditional flu jabs.
GlaxoSmithKline has submitted its plans to whip its troubled Quebec flu vaccine plant into shape to Health Canada, and the regulator says the action outline is up to snuff.
From Our Sister Sites
Further concentrating life science powerhouses around Boston, GE Healthcare Life Sciences will open a new U.S. headquarters in Marlborough, MA. It's expected to house more than 500 employees, including at least 220 new hires.
No price war on hepatitis C drugs? That would be a disappointment to payers worried about the cost of treating millions of patients with super-expensive, yet highly effective drugs. But to investors, that reassurance sounds really good.